company background image
R0V logo

Revenio Group Oyj MUN:R0V Stock Report

Last Price

€31.84

Market Cap

€607.4m

7D

0%

1Y

n/a

Updated

05 Sep, 2023

Data

Company Financials +

R0V Stock Overview

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.

R0V fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends4/6

Revenio Group Oyj Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Revenio Group Oyj
Historical stock prices
Current Share Price€31.84
52 Week High€33.32
52 Week Low€31.36
Beta1.45
1 Month Change0%
3 Month Change-0.13%
1 Year Changen/a
3 Year Change-7.84%
5 Year Changen/a
Change since IPO106.75%

Recent News & Updates

Recent updates

Shareholder Returns

R0VDE Medical EquipmentDE Market
7D0%-5.1%-1.5%
1Yn/a-9.0%0.9%

Return vs Industry: Insufficient data to determine how R0V performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how R0V performed against the German Market.

Price Volatility

Is R0V's price volatile compared to industry and market?
R0V volatility
R0V Average Weekly Movementn/a
Medical Equipment Industry Average Movement4.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: R0V has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine R0V's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001217Jouni Toijalawww.reveniogroup.fi

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging and DRSplus, a device for detection of diabetic retinopathy; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.

Revenio Group Oyj Fundamentals Summary

How do Revenio Group Oyj's earnings and revenue compare to its market cap?
R0V fundamental statistics
Market cap€607.38m
Earnings (TTM)€19.15m
Revenue (TTM)€98.03m

31.7x

P/E Ratio

6.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
R0V income statement (TTM)
Revenue€98.03m
Cost of Revenue€28.01m
Gross Profit€70.02m
Other Expenses€50.87m
Earnings€19.15m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Oct 26, 2023

Earnings per share (EPS)0.72
Gross Margin71.43%
Net Profit Margin19.54%
Debt/Equity Ratio19.4%

How did R0V perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

50%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.